As of Thursday close, Bolt Biotherapeutics Inc.’s (NASDAQ:BOLT) stock was up $0.08, moving up 5.41 percent to $1.56. The average number of shares traded per day over the past five days has been 527,520 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0800 gain in that time frame. In the last twenty days, the average volume was 348,205, while in the previous 50 days, it was 245,312.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, BOLT stock retreated -39.77%. Shares of the company fell to $1.3900 on 05/09/22, the lowest level in the past month. A 52-week high of $20.49 was reached on 01/03/22 after having rallying from a 52-week low of $1.39. Since the beginning of this year, BOLT’s stock price has dropped by -68.16% or -$3.3400, and marked a new high 1 time. However, the stock has declined by -92.39% since its 52-week high.
Bolt Biotherapeutics Inc. (BOLT) last reported insider trading activity 156 days ago on Dec 08. Quinn William P., the Chief Financial Officer of the company, purchased of 5,000 shares for $4.71 on Dec 08. It resulted in a $23,575 investment by the insider. Perez Edith A. added 411 shares at an average price of $4.64 on Dec 06. The insider now owns 1,328 shares following the transaction. On Dec 06, Chief Financial Officer Quinn William P. bought 35 shares at $4.64 apiece. The transaction was valued at $162.
In the three months ended September 29, Bolt Biotherapeutics Inc.’s quick ratio stood at 8.90, while its current ratio was 8.90, showing that the company is able to pay off its debt. Based on annual data, BOLT earned $1.26 million in gross profit and brought in $1.26 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.10%. Return on equity (ROE) for the past 12 months was -35.10%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BOLT’s revenue fell -2235.29% to $0.75 million during the quarter, while net income inched up to $0.51 million. While analysts expected Bolt Biotherapeutics Inc. to report -$0.65 quarterly earnings, the actual figure was -$0.63 per share, beating the consensus estimate by 3.10%. During the quarter, the company generated -$25.61 million in EBITDA. The liabilities of Bolt Biotherapeutics Inc. were 57.6 million at the end of its most recent quarter ended September 29, and its total debt was $24.93 million. The value of shareholders’ equity is $37.47 million.
This quick technical analysis looks at Bolt Biotherapeutics Inc.’s (BOLT) price momentum. With a historical volatility rate of 102.39%, the RSI 9-day stood at 38.18% on 12 May.
With respect to its five-day moving average, the current Bolt Biotherapeutics Inc. price is up by +5.41% percent or $0.0800. At present, BOLT shares trade -40.46% below its 20-day simple moving average and -65.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately -53.01% below its SMA50 and -87.12% below its SMA200.
Stochastic coefficient K was 28.22% and Stochastic coefficient D was 24.03%, while ATR was 0.1863. Given the Stochastic reading of 32.69% for the 14-day period, the RSI (14) reading has been calculated as 34.61%. As of today, the MACD Oscillator reading stands at 0.0211, while the 14-day reading stands at -0.0274.
Bolt Biotherapeutics Inc. downgraded its rating on Bolt Biotherapeutics Inc. (NASDAQ: BOLT) to an Equal-weight in a note to investors on January 06, 2022. The analysts firm previously had an Overweight rating on the stock.Bolt Biotherapeutics Inc. (BOLT) has been rated Buy by analysts. According to 0 brokerage firms, BOLT is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Bolt Biotherapeutics Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $7.00 – $16.00. Based on these forecasts, analysts predict Bolt Biotherapeutics Inc. (BOLT) will achieve an average price target of $9.75.